Trial
NCT02516696
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Celgene Corporation
Condition
Multiple Myeloma
Intervention
Clarithromycin
Why stopped
low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-05